SAN DIEGO, CA, November 6, 2017 – ChemDiv Inc., a fully integrated California-based CRO, announced today that Tri-Institutional Therapeutics Discovery Institute, Inc. (Tri-I TDI) will use ChemDiv's proprietary discovery chemistry platform to advance the Institute's robust R&D pipeline. The Tri-I TDI enables scientists in the Tri-Institutional community, made up of
Memorial Sloan Kettering Cancer Center,
The Rockefeller University and
Weill Cornell Medicine, to advance their ground breaking biological discoveries to preclinical studies. This collaboration with ChemDiv is aimed at assisting Tri-I TDI investigators with developing therapies across multiple therapeutic areas.
“Tri-I TDI strives to advance groundbreaking academic discoveries to preclinical studies in order to demonstrate their relevance in blocking disease initiation and progression. Our goal at ChemDiv is to apply our proficiency in small molecule chemistry and help our partner achieve their objective in the most efficient and productive way. We will use our expertise in discovery chemistry to assist the Institute with building and advancing an effective pipeline of programs that target a wide range of therapeutic areas,” commented Rouslan Michtchenko, Senior Director of Business Development at ChemDiv, Inc.
About ChemDivChemDiv is a recognized global leader in drug discovery solutions. Over the past 25+ years the ChemDiv team has delivered hundreds of leads, drug candidates and new drug approvals in the areas of CNS, oncology, virology, inflammation, immunology, cardio and metabolic diseases to its pharma, biotech and academic partners around the globe. ChemDiv’s integrated drug discovery and risk-share collaborative platforms allow for an accelerated, cost-effective R&D process aimed at rapidly bringing a project from target ID to Phase 3 clinical candidate and beyond.
http://www.chemdiv.com/Media Contact:
Ron Demuth
General Manager
ChemDiv inc.
rdemuth@chemdiv.com858.724.0581
SAN DIEGO, CA, November 6, 2017 – ChemDiv Inc., a fully integrated California-based CRO, announced today that Tri-Institutional Therapeutics Discovery Institute, Inc. (Tri-I TDI) will use ChemDiv's proprietary discovery chemistry platform to advance the Institute's robust R&D pipeline. The Tri-I TDI enables scientists in the Tri-Institutional community, made up of Memorial Sloan Kettering Cancer Center, The Rockefeller University and Weill Cornell Medicine, to advance their ground breaking biological discoveries to preclinical studies. This collaboration with ChemDiv is aimed at assisting Tri-I TDI investigators with developing therapies across multiple therapeutic areas.“Tri-I TDI strives to advance groundbreaking academic discoveries to preclinical studies in order to demonstrate their relevance in blocking disease initiation and progression. Our goal at ChemDiv is to apply our proficiency in small molecule chemistry and help our partner achieve their objective in the most efficient and productive way. We will use our expertise in discovery chemistry to assist the Institute with building and advancing an effective pipeline of programs that target a wide range of therapeutic areas,” commented Rouslan Michtchenko, Senior Director of Business Development at ChemDiv, Inc.About ChemDivChemDiv is a recognized global leader in drug discovery solutions. Over the past 25+ years the ChemDiv team has delivered hundreds of leads, drug candidates and new drug approvals in the areas of CNS, oncology, virology, inflammation, immunology, cardio and metabolic diseases to its pharma, biotech and academic partners around the globe. ChemDiv’s integrated drug discovery and risk-share collaborative platforms allow for an accelerated, cost-effective R&D process aimed at rapidly bringing a project from target ID to Phase 3 clinical candidate and beyond. http://www.chemdiv.com/Media Contact:Ron DemuthGeneral ManagerChemDiv inc.rdemuth@chemdiv.com858.724.0581 
